...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: To our scientist
6
Dec 04, 2020 09:09AM
6
Dec 04, 2020 09:29AM
4
Dec 05, 2020 01:19AM
5
Dec 05, 2020 10:03AM

I think this might also have be a factor Curious, as far as I know except for this cryptic anouncement, we have not been given any more information.

The combination of apabetalone and the SGLT2 inhibitors, in addition to standard of care medicines, resulted in a significant improvement of key renal function marker eGFR compared to SGLT2 inhibitors and placebo (p=0.05). Additionally, a significant reduction of plasma Hb1Ac was also observed in patients receiving the combination of apabetalone and the SGLT2 inhibitors, on top of standard of care treatment, compared to placebo (p<0.001). Details of these findings are planned to be submitted to a leading peer review journal in the near future.

 

6
Dec 05, 2020 02:28PM
6
Dec 07, 2020 05:32PM
2
Dec 07, 2020 07:41PM
8
Dec 07, 2020 07:46PM
4
Dec 07, 2020 07:56PM
3
Dec 07, 2020 07:59PM
2
Dec 07, 2020 09:12PM
2
Dec 07, 2020 10:25PM
2
Dec 07, 2020 10:31PM
1
Dec 07, 2020 11:15PM
4
Dec 08, 2020 09:20PM
Share
New Message
Please login to post a reply